Brought to you by 
U. of Chicago uses Vysis FISH for clinical genetic testing
13 Jul 1999
Executive Summary
Vysis Inc. has granted to the University of Chicago a non-exclusive, royalty bearing license to its Fluorescence In Situ Hybridization technology (FISH) which the University will use in its clinical genetics testing services to patients.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
U. of Chicago uses Vysis FISH for clinical genetic testing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice